Phaseline

Targets › RXFP1

RXFP1 (Relaxin receptor 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Cardiovascular, Genitourinary; next expected readout Dec 2026.

Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP. (UniProt, Q9HBX9)

Open in Phaseline: the race on RXFP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cambridge University Hospitals NHS Foundation TrustRelaxin
RLN2-encoded endogenous peptide hormone that binds to G protein-coupled receptor RXFP1
RLN2, RXFP1Phase 2Cardiovascular DiseasesDec 2026
River 2 RenalR2R01
Relaxin receptor agonist
RXFP1Phase 2Acute Kidney InjuryApr 2027

Conditions

Cardiovascular Diseases (1) Acute Kidney Injury (1)

Modalities

small molecule (2)

Companies

Cambridge University Hospitals NHS Foundation Trust (1) River 2 Renal (1)

Related targets

RLN2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.